Literature DB >> 16199531

Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells.

Udayan Chatterji1, Michael D Bobardt, Robyn Stanfield, Roger G Ptak, Luke A Pallansch, Priscilla A Ward, Maureen J Jones, Cheryl A Stoddart, Pietro Scalfaro, Jean-Maurice Dumont, Kamel Besseghir, Brigitte Rosenwirth, Philippe A Gallay.   

Abstract

In this study, we asked if a naturally occurring HIV-1 variant exists that circumvents CypA dependence in human cells. To address this issue, we sought viruses for CypA independence using Debio-025, a cyclosporine A (CsA) analog that disrupts CypA-capsid interaction. Surprisingly, viral variants from the Main group replicate even in the presence of the drug. Sequencing analyses revealed that these viruses encode capsid substitutions within the CypA-binding site (V86P/H87Q/I91V/M96I). When we introduced these substitutions into viruses that normally rely on CypA for replication, these mutants no longer depended on CypA, suggesting that naturally occurring capsid substitutions obviate the need for CypA. This is the first demonstration that isolates from the Main group naturally develop CypA-independent strategies to replicate in human cells. Surprisingly, we found that these capsid substitutions render HIV-1 capable of infecting Owl monkey (OMK) cells that highly restrict HIV-1. OMK cell resistance to HIV-1 is mediated via TRIM-Cyp, which arose from a retrotransposition of CypA into the TRIM5 alpha gene. Interestingly, saturation experiments suggest that the Pro86/Gln87/Val91/Ile96 capsid core is "invisible" to TRIM-Cyp. This study demonstrates that specific capsid substitutions can release HIV-1 from both CypA dependence in human cells and TRIM-Cyp restriction in monkey cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199531     DOI: 10.1074/jbc.M506314200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.

Authors:  Sonja I Gringhuis; Michiel van der Vlist; Linda M van den Berg; Jeroen den Dunnen; Manja Litjens; Teunis B H Geijtenbeek
Journal:  Nat Immunol       Date:  2010-04-04       Impact factor: 25.606

Review 2.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo.

Authors:  Marein A W P de Jong; Lot de Witte; Menno J Oudhoff; Sonja I Gringhuis; Philippe Gallay; Teunis B H Geijtenbeek
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

4.  Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.

Authors:  Michael D Bobardt; Udayan Chatterji; Lana Schaffer; Lot de Witte; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

5.  Recognition of the HIV capsid by the TRIM5α restriction factor is mediated by a subset of pre-existing conformations of the TRIM5α SPRY domain.

Authors:  Dmytro B Kovalskyy; Dmitri N Ivanov
Journal:  Biochemistry       Date:  2014-02-24       Impact factor: 3.162

6.  Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity.

Authors:  Zuzana Keckesova; Laura M J Ylinen; Greg J Towers
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity.

Authors:  Emilie Battivelli; Julie Migraine; Denise Lecossier; Patrick Yeni; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

8.  The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.

Authors:  T Tiepolo; A Angelin; E Palma; P Sabatelli; L Merlini; L Nicolosi; F Finetti; P Braghetta; G Vuagniaux; J-M Dumont; C T Baldari; P Bonaldo; P Bernardi
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

9.  Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells.

Authors:  Mingli Qi; Ruifeng Yang; Christopher Aiken
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

10.  Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Authors:  Roger G Ptak; Philippe A Gallay; Dirk Jochmans; Andrew P Halestrap; Urs T Ruegg; Luke A Pallansch; Michael D Bobardt; Marie-Pierre de Béthune; Johan Neyts; Erik De Clercq; Jean-Maurice Dumont; Pietro Scalfaro; Kamel Besseghir; Roland M Wenger; Brigitte Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.